JP2007513056A - 糖尿病性神経因性疼痛の処置および睡眠の改善のためのオキシカルバゼピンの使用 - Google Patents
糖尿病性神経因性疼痛の処置および睡眠の改善のためのオキシカルバゼピンの使用 Download PDFInfo
- Publication number
- JP2007513056A JP2007513056A JP2006525105A JP2006525105A JP2007513056A JP 2007513056 A JP2007513056 A JP 2007513056A JP 2006525105 A JP2006525105 A JP 2006525105A JP 2006525105 A JP2006525105 A JP 2006525105A JP 2007513056 A JP2007513056 A JP 2007513056A
- Authority
- JP
- Japan
- Prior art keywords
- day
- oxcarbazepine
- pain
- patient
- neuropathic pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 229960001816 oxcarbazepine Drugs 0.000 title claims abstract description 61
- 208000004296 neuralgia Diseases 0.000 title claims abstract description 45
- 208000021722 neuropathic pain Diseases 0.000 title claims abstract description 45
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 26
- 208000002193 Pain Diseases 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 208000000094 Chronic Pain Diseases 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
- 239000004480 active ingredient Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 31
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 230000002618 waking effect Effects 0.000 claims description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical class C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 abstract description 4
- 150000001875 compounds Chemical class 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 13
- 229940068196 placebo Drugs 0.000 description 13
- 239000003826 tablet Substances 0.000 description 3
- 208000004454 Hyperalgesia Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229940100692 oral suspension Drugs 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 229940061414 trileptal Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0320637A GB0320637D0 (en) | 2003-09-03 | 2003-09-03 | Organic compounds |
| US53737804P | 2004-01-16 | 2004-01-16 | |
| PCT/EP2004/009797 WO2005020968A2 (en) | 2003-09-03 | 2004-09-02 | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007513056A true JP2007513056A (ja) | 2007-05-24 |
| JP2007513056A5 JP2007513056A5 (enExample) | 2007-10-18 |
Family
ID=34276821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006525105A Pending JP2007513056A (ja) | 2003-09-03 | 2004-09-02 | 糖尿病性神経因性疼痛の処置および睡眠の改善のためのオキシカルバゼピンの使用 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20060270658A1 (enExample) |
| EP (1) | EP1663247B1 (enExample) |
| JP (1) | JP2007513056A (enExample) |
| KR (1) | KR20060118426A (enExample) |
| AT (1) | ATE446759T1 (enExample) |
| AU (1) | AU2004268381B2 (enExample) |
| BR (1) | BRPI0414112A (enExample) |
| CA (1) | CA2537060A1 (enExample) |
| DE (1) | DE602004023861D1 (enExample) |
| IL (1) | IL173822A0 (enExample) |
| IS (1) | IS8373A (enExample) |
| MA (1) | MA28036A1 (enExample) |
| MX (1) | MXPA06002392A (enExample) |
| NO (1) | NO20061515L (enExample) |
| RU (1) | RU2369393C2 (enExample) |
| SG (1) | SG146631A1 (enExample) |
| TN (1) | TNSN06072A1 (enExample) |
| WO (1) | WO2005020968A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
| GB0603008D0 (en) * | 2006-02-14 | 2006-03-29 | Portela & Ca Sa | Method |
| MX2008013675A (es) * | 2006-04-26 | 2009-03-06 | Supernus Pharmaceuticals Inc | Preparaciones de liberacion controlada de oxcarbacepina que tienen perfil de liberacion sigmoidal. |
| GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| KR102486435B1 (ko) | 2022-04-25 | 2023-01-10 | 주식회사 제이비플랜트 | 산업용 냉동기기의 친환경 패널의 제조 방법 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003047580A1 (en) * | 2001-11-30 | 2003-06-12 | The Boots Company Plc | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
| US4353887A (en) | 1979-08-16 | 1982-10-12 | Ciba-Geigy Corporation | Divisible tablet having controlled and delayed release of the active substance |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| GB9925962D0 (en) * | 1999-11-02 | 1999-12-29 | Novartis Ag | Organic compounds |
| GB9930058D0 (en) | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
| CA2497780A1 (en) * | 2002-10-17 | 2004-04-29 | Novartis Ag | Pharmaceutical composition for treating pain comprising oxicarbazepine, or derivatives thereof, and cox2 inhibitors |
-
2004
- 2004-09-02 WO PCT/EP2004/009797 patent/WO2005020968A2/en not_active Ceased
- 2004-09-02 JP JP2006525105A patent/JP2007513056A/ja active Pending
- 2004-09-02 CA CA002537060A patent/CA2537060A1/en not_active Abandoned
- 2004-09-02 US US10/570,340 patent/US20060270658A1/en not_active Abandoned
- 2004-09-02 AU AU2004268381A patent/AU2004268381B2/en not_active Ceased
- 2004-09-02 BR BRPI0414112-1A patent/BRPI0414112A/pt not_active IP Right Cessation
- 2004-09-02 DE DE602004023861T patent/DE602004023861D1/de not_active Expired - Lifetime
- 2004-09-02 RU RU2006110550/15A patent/RU2369393C2/ru not_active IP Right Cessation
- 2004-09-02 MX MXPA06002392A patent/MXPA06002392A/es not_active Application Discontinuation
- 2004-09-02 SG SG200806736-5A patent/SG146631A1/en unknown
- 2004-09-02 AT AT04764755T patent/ATE446759T1/de not_active IP Right Cessation
- 2004-09-02 EP EP04764755A patent/EP1663247B1/en not_active Expired - Lifetime
- 2004-09-02 KR KR1020067004340A patent/KR20060118426A/ko not_active Ceased
-
2006
- 2006-02-20 IL IL173822A patent/IL173822A0/en unknown
- 2006-03-02 TN TNP2006000072A patent/TNSN06072A1/en unknown
- 2006-03-10 MA MA28869A patent/MA28036A1/fr unknown
- 2006-03-24 IS IS8373A patent/IS8373A/is unknown
- 2006-04-03 NO NO20061515A patent/NO20061515L/no not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003047580A1 (en) * | 2001-11-30 | 2003-06-12 | The Boots Company Plc | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith |
Also Published As
| Publication number | Publication date |
|---|---|
| SG146631A1 (en) | 2008-10-30 |
| US20060270658A1 (en) | 2006-11-30 |
| CA2537060A1 (en) | 2005-03-10 |
| KR20060118426A (ko) | 2006-11-23 |
| WO2005020968A3 (en) | 2005-05-19 |
| BRPI0414112A (pt) | 2006-10-31 |
| MXPA06002392A (es) | 2006-06-20 |
| EP1663247B1 (en) | 2009-10-28 |
| IS8373A (is) | 2006-03-24 |
| ATE446759T1 (de) | 2009-11-15 |
| AU2004268381B2 (en) | 2009-06-18 |
| TNSN06072A1 (en) | 2007-10-03 |
| DE602004023861D1 (de) | 2009-12-10 |
| WO2005020968A2 (en) | 2005-03-10 |
| RU2369393C2 (ru) | 2009-10-10 |
| MA28036A1 (fr) | 2006-07-03 |
| AU2004268381A1 (en) | 2005-03-10 |
| IL173822A0 (en) | 2006-07-05 |
| EP1663247A2 (en) | 2006-06-07 |
| RU2006110550A (ru) | 2007-12-20 |
| NO20061515L (no) | 2006-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6511985B1 (en) | Combination of cerivastatin and fibrates | |
| US11890261B2 (en) | Composition and method for treating neurological disease | |
| US20090192142A1 (en) | Use of carbamazepine derivatives for the treatment of agitation in dementia patients | |
| US10500170B2 (en) | Composition and method for treating neurological disease | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| US4481206A (en) | Spiro succinimide derivative in the treatment of dementia of the Alzheimer type | |
| JP2007513056A (ja) | 糖尿病性神経因性疼痛の処置および睡眠の改善のためのオキシカルバゼピンの使用 | |
| US11833121B2 (en) | Composition and method for treating neurological disease | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| DE69910600T2 (de) | Verwendung von metformin gegen die gewichtszunahme, die mit valproat und andere psychotropische arzneimittel verbunden ist | |
| US4663345A (en) | Etodolac for treatment of gout | |
| ZA200601502B (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and improvement of sleep | |
| Broncel et al. | Bisoprolol in the treatment of hypertension in the elderly | |
| EP1225889A2 (de) | Arzneimittelkombinationen von nifedipin und cerivastatin | |
| WO2004105771A1 (de) | Kombination von acetylsalicylsäure und alpha-glucosidase-inhibitoren | |
| BE894110A (fr) | Utilisation de la trazodone dans le traitement des ulceres gastro-intestinaux | |
| MXPA01006136A (en) | Combination of cerivastatin and fibrates |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070903 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070903 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110301 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |